Uptake and retention of the photosensitizer mono-L-asparthyl chlorine e6 in experimental malignant glioma.
The objective of the study was to investigate the potential of mono-L-aspartyl chlorine e6 (NPe6), a water-soluble photosensitizer derived from chlorophyll, for use in photodynamic diagnosis (PDD) of malignant brain tumor. A C6 glioma cell line was transplanted in the SD rat brain to create a brain tumor model. Five days after transplantation, NPe6 was administrated via the tail vein at concentrations ranging from 1.25 to 10 mg/kg; then the skull was opened in the rat brain, the site of tumor transplant was irradiated with a diode laser beam at 664 nm, and the time-course intensity and distribution of emerging fluorescence were observed. Furthermore, the correlation between fluorescence distribution and histopathological findings was investigated in the removed brain. Fluorescence was observed in the site of brain tumor transplant from 5 min after injection, and stable fluorescence was recognized at the site until 4 h after administration. No differences were noted in fluorescence intensity at NPe6 doses of 2.5 mg/kg or more; therefore, it was possible to estimate the optimal dose range. Fluorescence distribution had a clear correlation with tumor cell density, and it was possible to capture the margin of tumor cell invasion with fluorescence. The photosensitizer NPe6 is capable of assessing tumor cell density in malignant glioma tissue in terms of differences in fluorescence intensity. The usefulness of PDD using 5-aminoleveulinic acid during surgery for malignant glioma has been recognized in recent years. The results of the present study suggested the potential of NPe6 as a promising photosensitizer for use in PDD for accurate grasp of the extent of removal during the course of malignant glioma surgery.
Matsumura
Hiroyuki
H
Department of Neurosurgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku, Tokyo 160-0023, Japan.
Akimoto
Jiro
J
Haraoka
Jo
J
Aizawa
Katsuo
K
D000818:Animals; D001932:Brain Neoplasms / Q000175:diagnosis*; D045744:Cell Line, Tumor; D005910:Glioma / Q000175:diagnosis*; D007834:Lasers; D008297:Male; D009368:Neoplasm Transplantation; D017319:Photosensitizing Agents / Q000493:pharmacokinetics*; D011166:Porphyrins / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
D017319:Photosensitizing Agents; D011166:Porphyrins; C053434:Talaporfin
Photochem Photobiol. 1987 Jun;45(6):879-89
2957705
Lasers Surg Med. 2000;26(1):83-9
10637007
J Clin Laser Med Surg. 1996 Oct;14(5):263-70
9612192
Photochem Photobiol. 1995 Jun;61(6):646-9
7568411
Lasers Surg Med. 1989;9(2):90-101
2523995
Cancer Res. 1978 Aug;38(8):2628-35
667856
Gan To Kagaku Ryoho. 2000 Oct;27(12):1876-8
11086434
Cancer Res. 1990 Jul 1;50(13):3985-90
2354446
Lancet Oncol. 2006 May;7(5):392-401
16648043
Photochem Photobiol. 1987 Nov;46(5):789-93
3441501
Photochem Photobiol. 1992 Jul;56(1):51-6
1508982
Neurosurgery. 1990 Feb;26(2):248-54
2137904
Hepatology. 1989 Dec;10 (6):995-7
2583692
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1785-9
1542672
J Photochem Photobiol B. 1997 May;39(1):81-3
9210325
Photochem Photobiol. 1989 Aug;50(2):221-8
2528753
Neurosurgery. 1998 May;42(5):1044-55; discussion 1055-6
9588549
Cancer Res. 1992 May 15;52(10):2890-3
1581904
Neurosurgery. 1985 Dec;17(6):883-90
2934641
Semin Surg Oncol. 1995 Sep-Oct;11(5):335-45
7569555
Lasers Surg Med. 1989;9(2):102-8
2523992
Cancer Res. 1987 Sep 1;47(17):4681-5
2957047
J Neurosurg. 1988 Jul;69(1):1-14
3288722
J Neurosurg. 1948 Jul;5(4):392-8
18872412
Cancer. 1998 Jan 15;82(2):421-7
9445202
J Natl Cancer Inst. 1988 May 4;80(5):330-6
2965763
Cancer Res. 1994 Sep 1;54(17):4564-8
8062241
J Natl Cancer Inst. 1988 Dec 21;80(20):1599-605
2973528
Neurosurgery. 1988 Nov;23(5):557-63
2849067
J Photochem Photobiol B. 1992 Jul 30;14 (4):275-92
1403373
Photochem Photobiol. 1996 Oct;64(4):671-5
8863472
J Neurosurg. 2000 Dec;93(6):1003-13
11117842
J Neurosurg Sci. 1980 Jul-Dec;24(3-4):119-29
6267229
J Neurosurg. 2001 Aug;95(2):190-8
11780887